[177Lu]Lu-edotreotide significantly extends progression-free survival over everolimus in advanced GEP NETs
Background
Patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs) face limited treatment options, with peptide receptor radionuclide therapy (PRRT) and targeted molecular therapy being approved. However, clinical guidance on the optimal sequencing of these therapies remains scarce, leaving a critical gap in patient management. Current standard-of-care often involves somatostatin receptor-positive GEP NETs being treated with PRRT like [¹⁷⁷Lu]Lu-DOTATATE, or targeted agents such as everolimus, an mTOR inhibitor. This trial directly compares these two modalities to inform preferred treatment strategies.
Study Design
This phase 3, open-label, superiority trial enrolled 324 patients (age 18+) with unresectable or metastatic grade 1-2 GEP NETs that were somatostatin receptor-positive. Patients were randomized 2:1 to receive intravenous [177Lu]Lu-edotreotide (7.5 ± 0.7 GBq every 3 months, maximum four cycles) or oral everolimus (10 mg/day) for up to 30 months. Randomization was stratified by primary tumor origin and previous therapy. The primary endpoint was progression-free survival (PFS), assessed via blinded independent central review. Harms were evaluated in all patients receiving at least one dose.
Results
Between April 13, 2017, and June 20, 2022, 309 patients were randomized: 207 to the [177Lu]Lu-edotreotide group and 102 to the everolimus group. The median follow-up for progression-free survival was 27.5 months (IQR 19.6-30.4) for the [177Lu]Lu-edotreotide group and 21.2 months (IQR 8.9-29.4) for the everolimus group. The study found that:
Median progression-free survival was significantly longer with [177Lu]Lu-edotreotide compared to everolimus. While the abstract explicitly states a significant difference, specific median PFS values for the everolimus arm and the precise statistical significance (e.g., hazard ratio, p-value) for the primary endpoint were not provided in the excerpt. Harms data were collected but not detailed in this abstract.
Key Findings
- 309 patients with advanced GEP NETs were randomized 2:1 to [177Lu]Lu-edotreotide or everolimus.
- Median follow-up for PFS was 27.5 months for [177Lu]Lu-edotreotide and 21.2 months for everolimus.
- Median progression-free survival was significantly longer with [177Lu]Lu-edotreotide.
- The trial directly compared PRRT ([177Lu]Lu-edotreotide) against targeted therapy (everolimus) for the first time in this setting.
Why It Matters
This landmark COMPETE trial provides crucial evidence for the preferred sequencing of therapies in advanced GEP NETs. [177Lu]Lu-edotreotide demonstrates superior efficacy over everolimus, suggesting it should be considered as an earlier-line or first-line treatment option for patients with progressive, somatostatin receptor-positive GEP NETs. This finding could shift clinical practice, potentially improving patient outcomes by extending disease control. For clinicians, this means a stronger rationale for initiating PRRT with [177Lu]Lu-edotreotide over an mTOR inhibitor in this patient population. The protocol involved specific dosing of 7.5 ± 0.7 GBq every 3 months for up to four cycles, providing a clear framework for clinical application.
lu-edotreotide
everolimus
gep-nets
neuroendocrine-tumors
prrt
phase-3-trial